Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 5/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15937310 | 1.00 | RARA (0.35) | RARARARBRARGPGRPDK2 | |
| SCHEMBL13371154 | 1.00 | RARA (0.35) | RARARARBRARGPGRPDK2 | |
| SCHEMBL15937344 | 1.00 | RARA (0.35) | RARARARBRARGPGRPDK2 | |
| SCHEMBL13371874 | 0.97 | RARA (0.35) | RARARARBRARGPGRPDK2 | |
| SCHEMBL13371089 | 0.97 | KMT2A (0.34) | RARARARBRARGPGRPDK2 | |
| SCHEMBL15937363 | 0.97 | KMT2A (0.34) | RARARARBRARGPGRPDK2 | |
| SCHEMBL15937277 | 0.97 | KMT2A (0.34) | RARARARBRARGPGRPDK2 | |
| SCHEMBL15937330 | 0.97 | KMT2A (0.34) | RARARARBRARGPGRPDK2 | |
| SCHEMBL13352788 | 0.96 | RARA (0.36) | RARARARBRARGPGRPDK2 | |
| SCHEMBL13353345 | 0.96 | RARA (0.36) | RARARARBRARGPGRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160126476-A1 | NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE | LMS CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-20160126476-A1 | NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE | LMS CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| WO-2014119895-A1 | NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE | 주식회사 엘엠에스 (KR) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160126476-A1 | NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE | ELAVL1, SUN2, PER2 | RARA 1705/4885RARB 1937/4885RARG 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.